KR20200139737A - 개선된 물리적 안정성 및 향상된 항종양 효능을 위한 미셀에서의 올리고락트산 접합체의 입체복합체 - Google Patents

개선된 물리적 안정성 및 향상된 항종양 효능을 위한 미셀에서의 올리고락트산 접합체의 입체복합체 Download PDF

Info

Publication number
KR20200139737A
KR20200139737A KR1020207031253A KR20207031253A KR20200139737A KR 20200139737 A KR20200139737 A KR 20200139737A KR 1020207031253 A KR1020207031253 A KR 1020207031253A KR 20207031253 A KR20207031253 A KR 20207031253A KR 20200139737 A KR20200139737 A KR 20200139737A
Authority
KR
South Korea
Prior art keywords
lactic acid
gemcitabine
oligo
gem
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207031253A
Other languages
English (en)
Korean (ko)
Inventor
글렌 에스. 권
유 통 탬
Original Assignee
위스콘신 얼럼나이 리서어치 화운데이션
위스콘신 얼럼나이 리서어치 화운데이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 위스콘신 얼럼나이 리서어치 화운데이션, 위스콘신 얼럼나이 리서어치 화운데이션 filed Critical 위스콘신 얼럼나이 리서어치 화운데이션
Publication of KR20200139737A publication Critical patent/KR20200139737A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020207031253A 2018-04-02 2019-04-01 개선된 물리적 안정성 및 향상된 항종양 효능을 위한 미셀에서의 올리고락트산 접합체의 입체복합체 Ceased KR20200139737A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862651365P 2018-04-02 2018-04-02
US62/651,365 2018-04-02
PCT/US2019/025174 WO2019195164A1 (en) 2018-04-02 2019-04-01 Stereocomplex of oligolactic acid conjugates in micelles for improved physical stability and enhanced antitumor efficacy

Publications (1)

Publication Number Publication Date
KR20200139737A true KR20200139737A (ko) 2020-12-14

Family

ID=66175512

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207031253A Ceased KR20200139737A (ko) 2018-04-02 2019-04-01 개선된 물리적 안정성 및 향상된 항종양 효능을 위한 미셀에서의 올리고락트산 접합체의 입체복합체

Country Status (6)

Country Link
US (2) US20210128736A1 (https=)
JP (1) JP7495352B2 (https=)
KR (1) KR20200139737A (https=)
CN (1) CN112105390A (https=)
CA (1) CA3095788A1 (https=)
WO (1) WO2019195164A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110652595B (zh) * 2019-10-21 2022-11-29 南通大学附属医院 一种聚亮氨酸-聚天冬氨酸嵌段共聚物立构复合载药胶束及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8416234D0 (en) 1984-06-26 1984-08-01 Ici Plc Biodegradable amphipathic copolymers
KR0180334B1 (ko) 1995-09-21 1999-03-20 김윤 블럭 공중합체 미셀을 이용한 약물전달체 및 이에 약물을 봉입하는 방법
JP5048690B2 (ja) * 2006-03-08 2012-10-17 クローズ 特に種子発芽および植物発生のための遅延性効果の農業処理剤
US8668919B2 (en) * 2009-03-03 2014-03-11 Abbott Cardiovascular Systems Inc. Polymer for creating hemocompatible surface
CN103599073A (zh) * 2013-11-15 2014-02-26 无锡中科光远生物材料有限公司 一种负载有靶向抗癌药物的plga微米颗粒的制备方法
CN104961786B (zh) * 2015-06-05 2018-09-25 苏州大学 基于吉西他滨结构的前体药物及其应用
ES2804251T3 (es) 2016-03-14 2021-02-05 Wisconsin Alumni Res Found Conjugados y micelas de ácido oligoláctico con eficacia anticáncer mejorada
WO2017201407A1 (en) * 2016-05-20 2017-11-23 Massachusetts Institute Of Technology Hydrogel particle of cystamine cross-linked dextran aldehyde containing imine conjugated doxorubicin and rgd peptide for chemotherapy

Also Published As

Publication number Publication date
US20240207416A1 (en) 2024-06-27
JP2021520344A (ja) 2021-08-19
CN112105390A (zh) 2020-12-18
US20210128736A1 (en) 2021-05-06
JP7495352B2 (ja) 2024-06-04
WO2019195164A1 (en) 2019-10-10
CA3095788A1 (en) 2019-10-10

Similar Documents

Publication Publication Date Title
EP2913353B1 (en) Amphiphilic block copolymer and preparation method thereof and micellar drug-loading system formed by same with antitumor drug
CN111819217B (zh) 一种两亲性嵌段共聚物及其制备方法和纳米胶束载药系统
EP2309989B1 (en) Drug loaded polymeric nanoparticles and methods of making and using same
JP5544357B2 (ja) 水酸基を有する生理活性物質の高分子結合体
US10980891B2 (en) Oligolactic acid conjugates and micelles with enhanced anticancer efficacy
EP2641605B1 (en) Polymer derivative of cytidine metabolism antagonist
EP1670838B1 (en) Amphiphilic block copolymer and polymeric composition comprising the same for drug delivery
Zhang et al. Fmoc-conjugated PEG-vitamin E2 micelles for tumor-targeted delivery of paclitaxel: enhanced drug-carrier interaction and loading capacity
US20240207416A1 (en) Stereocomplex of oligolactic acid conjugates in micelles for improved physical stability and enhanced antitumor efficacy
Tong et al. Establishment of a leucine-based poly (ester amide) s library with self-anticancer effect as nano-drug carrier for colorectal cancer treatment
CN104096237A (zh) 一种Pluronics-紫杉醇两亲性大分子前药及其胶束制剂
CN105012234B (zh) 一种二甲氧基姜黄素聚合物胶束及其制备方法与医药用途
CN102309763B (zh) 一种药物组合物及其制备方法
Lei et al. Co-delivery of paclitaxel and gemcitabine via folic acid-conjugated polymeric multi-drug nanoparticles (FA-PMDNPs) for the treatment of breast cancer.
HK40002729A (en) Oligolactic acid conjugates and micelles with enhanced anticancer efficacy

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13 Administrative time limit extension granted

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T13-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13 Administrative time limit extension granted

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T13-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000